Morgan Stanley Maintains Overweight on Monopar Therapeutics, Raises Price Target to $133
Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.
Last updated: 2026-11-19 08:30:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Monopar Therapeutics Inc. (MNPR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $70.87, with a market capitalization of $481.56M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $50.07 to $124.82. This page covers its latest market performance, valuation, price trends and company information.
$481.56M | |
$70.80 | |
$72.68 | |
$69.96 | |
$71.06 | |
92.22K | |
153.47K | |
-- | |
$124.82 | |
$50.07 | |
-- | |
2026-09-30 |
Monopar Therapeutics Inc. (MNPR) last closed at $70.87 as of 2026-11-19 01:00:00, down 0.25% ($0.18) from the previous close of $71.06.
During the latest regular trading session, MNPR traded between $69.96 and $72.68, with a volume of 92.22K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Monopar Therapeutics Inc. (MNPR) moved from $71.78 to $70.87, representing a decline of 1.27% ($0.92).
The stock traded between $67.12 and $75.59 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 170.27 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 27.8%
MNPR is currently trading at $70.87, placing it 27.8% of the way from its 52-week low of $50.07 to its 52-week high of $124.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 22 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Monopar Therapeutics Inc. and MNPR stock.
Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.80) by 10 percent. This is a 50 percent decrease over losses of $(0.48) per share from
Eligible investors can buy real shares of Monopar Therapeutics Inc. (MNPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MNPR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MNPR shares and USD.
MNPR Shares to USD
1.00 MNPR shares = 70.865 USD
Calculations are estimates based on the latest available price and are for reference only.